

ORIGINAL ARTICLE

Randomized Trial of Fetal Surgery for Moderate Left Diaphragmatic Hernia

Jan A. Deprest, M.D., Ph.D., Alexandra Benachi, M.D., Ph.D.,
Eduard Gratacos, M.D., Ph.D., Kypros H. Nicolaides, M.D.,
Christoph Berg, M.D., Ph.D., Nicola Persico, M.D., Ph.D., Michael Belfort, M.D., Ph.D.,
Glenn J. Gardener, M.D., Ph.D., Yves Ville, M.D., Ph.D., Anthony Johnson, M.D.,
Francesco Morini, M.D., Ph.D., Mirosław Wielgoś, M.D., Ph.D.,
Ben Van Calster, Ph.D., and Philip L.J. DeKoninck, M.D., Ph.D.,
for the TOTAL Trial for Moderate Hypoplasia Investigators*

ABSTRACT

BACKGROUND

Fetoscopic endoluminal tracheal occlusion (FETO) has been associated with increased postnatal survival among infants with severe pulmonary hypoplasia due to isolated congenital diaphragmatic hernia on the left side, but data are lacking to inform its effects in infants with moderate disease.

METHODS

In this open-label trial conducted at many centers with experience in FETO and other types of prenatal surgery, we randomly assigned, in a 1:1 ratio, women carrying singleton fetuses with a moderate isolated congenital diaphragmatic hernia on the left side to FETO at 30 to 32 weeks of gestation or expectant care. Both treatments were followed by standardized postnatal care. The primary outcomes were infant survival to discharge from a neonatal intensive care unit (NICU) and survival without oxygen supplementation at 6 months of age.

RESULTS

In an intention-to-treat analysis involving 196 women, 62 of 98 infants in the FETO group (63%) and 49 of 98 infants in the expectant care group (50%) survived to discharge (relative risk, 1.27; 95% confidence interval [CI], 0.99 to 1.63; two-sided $P=0.06$). At 6 months of age, 53 of 98 infants (54%) in the FETO group and 43 of 98 infants (44%) in the expectant care group were alive without oxygen supplementation (relative risk, 1.23; 95% CI, 0.93 to 1.65). The incidence of preterm, prelabor rupture of membranes was higher among women in the FETO group than among those in the expectant care group (44% vs. 12%; relative risk, 3.79; 95% CI, 2.13 to 6.91), as was the incidence of preterm birth (64% vs. 22%, respectively; relative risk, 2.86; 95% CI, 1.94 to 4.34), but FETO was not associated with any other serious maternal complications. There were two spontaneous fetal deaths (one in each group) without obvious cause and one neonatal death that was associated with balloon removal.

CONCLUSIONS

This trial involving fetuses with moderate congenital diaphragmatic hernia on the left side did not show a significant benefit of FETO performed at 30 to 32 weeks of gestation over expectant care with respect to survival to discharge or the need for oxygen supplementation at 6 months. FETO increased the risks of preterm, prelabor rupture of membranes and preterm birth. (Funded by the European Commission and others; TOTAL ClinicalTrials.gov number, NCT00763737.)

From the Department of Obstetrics and Gynecology, University Hospitals KU Leuven (J.A.D., P.L.J.D.) and Academic Department of Development and Regeneration, Biomedical Sciences, KU Leuven, Leuven, Belgium (J.A.D., B.V.C., P.L.J.D.); Hospital Antoine-Béclère, Université Paris-Saclay, Clamart (A.B.), and Necker-Enfants Malades Hospital, Paris (Y.V.) — both in France; Hospital Clinic and Sant Joan de Déu, Barcelona (E.G.); Institute for Women's Health, University College London Hospital (J.A.D.) and King's College Hospital (K.H.N.) — both in London; the University Hospital Bonn, Bonn, Germany (C.B.); Hospital Maggiore Policlinico, Milan (N.P.), and Bambino Gesù Children's Hospital, Rome (F.M.) — both in Italy; Baylor College of Medicine and Texas Children's Hospital (M.B.) and Children's Memorial Hermann Hospital (A.J.) — all in Houston; Mater Mothers' Hospital, Brisbane, QLD, Australia (G.J.G.); the Medical University of Warsaw, Warsaw, Poland (M.W.); and Erasmus MC-University Medical Center Rotterdam, Rotterdam, the Netherlands (P.L.J.D.). Address reprint requests to Dr. Deprest at the Department of Obstetrics and Gynecology, University Hospitals KU Leuven, and Academic Department of Development and Regeneration, Biomedical Sciences, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium, or at jan.deprest@uzleuven.be.

*The TOTAL Trial for Moderate Hypoplasia Investigators are listed in the Supplementary Appendix, available at NEJM.org.

This article was published on June 8, 2021, at NEJM.org.

N Engl J Med 2021;385:119-29.

DOI: 10.1056/NEJMoa2026983

Copyright © 2021 Massachusetts Medical Society.

CONGENITAL DIAPHRAGMATIC HERNIA is a surgically correctable defect, but it causes pulmonary hypoplasia, which is characterized by underdeveloped airways and pulmonary vessels.¹ Congenital diaphragmatic hernia is associated with a high risk of neonatal death and complications, mostly because of pulmonary hypertension and the need for long-term oxygen supplementation.^{2,3}

Prenatal congenital diaphragmatic hernia can be classified as severe, moderate, or mild, with expected postnatal survival of approximately 20%, 55%, and 85%, respectively. Expected postnatal survival is based on the quotient of observed-to-expected lung-to-head ratios (i.e., the ratio of the observed lung area to head circumference [measured on ultrasonography] divided by the ratio of that which would be expected in a healthy fetus of the same gestational age) as well as on whether there is intrathoracic herniation of the liver.^{4,5} The quotient of the observed-to-expected lung-to-head ratios is also predictive of early neonatal complications such as the need for supplemental oxygen and of the durations of stay in the neonatal intensive care unit (NICU), use of assisted ventilation, and time to full enteral feeding.⁶⁻⁸

Experimental data have shown that prenatal tracheal occlusion attenuates pulmonary hypoplasia⁹ because entrapped lung fluid activates stretch receptors and induces airway proliferation.¹⁰ Clinically, this technique involves percutaneous fetoscopic endoluminal tracheal occlusion (FETO) with a balloon (video). Prenatal reversal of the occlusion induces maturation.^{11,12} Studies have shown that in fetuses with severe left congenital diaphragmatic hernia, as compared with historical controls, FETO performed at a median gestation of 27 weeks has been associated with greater survival (49% vs. 24%)¹³ and fewer early neonatal respiratory complications,^{7,8} at the expense of an increased risk of prematurity.^{14,15} These studies have also shown a direct relationship between lung size at the time of fetal surgery and later lung growth and survival. In other words, among fetuses with severe pulmonary hypoplasia, those with a higher quotient of the observed-to-expected lung-to-head ratios had a better response to FETO than those with a lower ratio.^{16,17}

This finding prompted us to conduct the randomized Tracheal Occlusion to Accelerate Lung

Growth (TOTAL) trial (<https://www.totaltrial.eu>) to compare FETO with expectant prenatal care in women carrying fetuses with moderate congenital diaphragmatic hernia. Both groups received standardized postnatal care.^{18,19} To reduce the risk of very premature birth, FETO was performed at 30 to 32 weeks of gestation.

METHODS

TRIAL DESIGN AND PARTICIPANTS

This multicenter, open-label, adaptive, parallel-group, superiority trial involving women carrying singleton fetuses with moderate congenital diaphragmatic hernia on the left side was conducted at 12 FETO centers and 46 additional neonatal care centers in Belgium, France, Spain, the United Kingdom, Germany, Italy, Australia, the United States, Poland, Austria, Israel, Switzerland, the Netherlands, the Czech Republic, and Norway (see Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). To participate, the FETO centers had to have performed a minimum of 36 fetoscopies per year, irrespective of the indication; to have performed a minimum of 15 FETO procedures at the time of recruitment; and to have experience with standardized assessment of fetuses with congenital diaphragmatic hernia.⁵

All the women were assessed for eligibility at the FETO centers. The inclusion criteria were a maternal age of 18 years or more, singleton pregnancy, a gestational age at randomization of less than 31 weeks 5 days, congenital diaphragmatic hernia on the left side with no other major structural or chromosomal defects, and moderate pulmonary hypoplasia (defined as the quotient of observed-to-expected lung-to-head ratios of 25.0 to 34.9%, irrespective of liver position, or 35.0 to 44.9% with intrathoracic liver herniation).^{4,5} The exclusion criteria were maternal conditions that would make fetal surgery risky, technical limitations precluding fetal surgery (including those caused by severe maternal obesity, uterine fibroids, or both), an elevated risk of preterm birth (cervical length <15 mm, müllerian anomalies, or placenta previa), and psychological, socioeconomic, or other factors that might prevent adherence to the protocol (available at NEJM.org). We kept a log of eligible nonparticipants and their outcomes.



A video showing the FETO procedure is available at NEJM.org

Eligible women received multidisciplinary counseling and standard information on congenital diaphragmatic hernia and FETO,²⁰ as well as information about the concept of a randomized trial.²¹ Fetoscopic placement of a tracheal balloon was carried out at 30 weeks to 31 weeks 6 days of gestation. Reversal of occlusion, either by fetoscopy or by ultrasound-guided puncture of the balloon, was scheduled at 34 weeks 0 days to 34 weeks 6 days of gestation.²² The women who were assigned to FETO agreed to live near the FETO center for the duration of tracheal occlusion. If preterm birth was imminent, emergency balloon retrieval was performed in utero (as described above), at the time of delivery while the umbilical cord still connected the infant to the placenta, or by direct puncture immediately after delivery.²³ After balloon removal, the women were given the option of either delivering in the FETO center or returning home for delivery in their local tertiary referral hospital. In either case, postnatal care was standardized according to international consensus guidelines and was the same for both groups.^{18,19}

Approval for the trial was obtained from the relevant research ethics committees and competent authorities in each country. The statistical analysis plan is available with the protocol. The first author vouches for the fidelity of the trial to the protocol and for the accuracy and completeness of the data.

RANDOMIZATION

After assessment for eligibility, the women were randomly assigned, in a 1:1 ratio, to one of the two treatment groups, without stratification factors. Randomization was performed by a fetal medicine specialist using a purposely developed secure website. Block randomization was used for an equal distribution per group at every analysis (a single block for each analysis). The randomization sequence was generated by the statistician.

OUTCOME MEASURES

The initial primary outcome was survival to discharge without bronchopulmonary dysplasia.²⁴ At the prespecified administrative review, while the data were still blinded, the data monitoring and safety committee redefined the primary outcome as survival to discharge from the NICU. The committee also expanded the time point for

the need for oxygen supplementation to 6 months; survival to 6 months without oxygen supplementation became one of the two primary outcome measures. Oxygen supplementation was defined as any need for additional oxygen for respiratory support delivered by nasal cannula, high-flow devices, continuous positive airway pressure ventilation, or mechanical ventilation. The secondary and exploratory outcomes included surgical and pregnancy complications, fetal and neonatal survival, and complications in early infancy (Table S2).

STATISTICAL ANALYSIS

Our trial had a group-sequential design and five interim analyses to enable early stopping for clear superiority, with a two-sided alpha level of 5% with an O'Brien–Fleming alpha-spending function²⁵ and a power of 80%. Assuming that survival to discharge that was 20 percentage points higher in the FETO group than in the expectant care group would be highly relevant, 98 participants per group would be required if the trial was not discontinued early. The design could lead to a statistically significant result with an observed absolute increase of approximately 15 percentage points in survival to discharge, which was still considered to be clinically relevant. No formal boundaries for futility were considered. Details on sample-size considerations for the two primary outcomes and other details are provided in the statistical analysis plan, which is available with the protocol.

We analyzed the two primary outcomes using the z test for proportions according to the intention-to-treat principle. To control for multiplicity, significance testing for the two primary outcomes was performed only if the result for survival to discharge was statistically significant. A secondary analysis was performed according to the per-protocol principle. Secondary outcomes were analyzed only according to the intention-to-treat principle, without formal significance testing. We report relative risks, differences in percentages, and differences in medians with 95% confidence intervals because there was no adjustment for multiplicity in the analyses of secondary and exploratory outcomes. These confidence intervals should not be used to infer definitive treatment effects. Safety outcomes and adverse events are reported descriptively.

RESULTS

TRIAL PARTICIPANTS

Recruitment started in October 2008 and was completed in May 2019. A total of 1411 women

carrying fetuses with congenital diaphragmatic hernia underwent preliminary assessment, and 379 met the inclusion criteria; of these women, 196 (51.7%) provided written informed consent to participate and were randomly assigned to




Figure 1. Screening, Randomization, and Analysis.

Among the women who were excluded from the fetoscopic endoluminal tracheal occlusion (FETO) group after inclusion in the intention-to-treat analysis, four chose expectant care and three had contraindications to FETO (one had a short cervix, one had spontaneous membrane rupture, and in one there was an unfavorable fetal position before FETO was attempted). In another participant who was excluded from the FETO group, the fetal mouth was not accessible after trocar insertion into the amniotic cavity, and a balloon was not inserted. Two fetuses had major congenital abnormalities that were diagnosed after randomization (Simpson–Golabi–Behmel syndrome in one fetus and a mutation in the gene encoding filamin A [*FLNA*] in the other).

FETO (98 women) or expectant care (98 women) (Fig. 1). None of the participants withdrew consent or were lost to follow-up; thus, all the participants were included in the intention-to-treat analysis. This intention-to-treat analysis included 6 cases of genetic, syndromic, or severe structural abnormalities in the FETO group and 3 cases in the expectant care group. Some of these abnormalities, which were diagnosed either before or after birth, led to exclusion from the per-protocol analysis (details are provided in Table S3). In the FETO group, 10 women in the intention-to-treat analysis were excluded from the per-protocol analysis, including 8 who did not undergo FETO but received expectant care, and 2 who had infants in whom there was a postnatal diagnosis of a genetic abnormality for which postnatal palliative care was warranted (details are provided in Fig. 1). In the expectant care group,

3 participants did not receive the assigned intervention because they chose pregnancy termination. Therefore, 88 participants in the FETO group and 95 participants in the expectant care group were included in the per-protocol analysis (Fig. 1).

The baseline characteristics of the participants were similar in the two groups (Table 1). In the FETO group, the procedure was carried out in 91 of 98 of the women (93%) who had undergone randomization, and a balloon was successfully inserted in the fetal trachea in all but 1 woman (Table S4). In 3 fetuses, spontaneous balloon deflation was first observed at 31 weeks 0 days of gestation, 32 weeks 3 days of gestation, and 32 weeks 4 days of gestation, respectively. In 1 fetus, a second balloon was inserted at 33 weeks 1 day, and this balloon also spontaneously deflated. In 54 of the 90 women in whom

Table 1. Baseline Characteristics of the Mothers and Infants.*

Characteristic	FETO Group (N=98)	Expectant Care Group (N=98)
Median maternal age (IQR) — yr	31.1 (27.5–33.7)	31.6 (27.4–34.9)
Median gestational age at randomization (IQR) — wk	28.4 (26.6–29.6)	28.2 (27.0–29.3)
Nulliparous women — no. (%)	45 (46)	48 (49)
Median BMI (IQR)†	23.8 (20.4–28.2)	22.2 (21.0–25.9)
Cigarette smoker — no. (%)	11 (11)	8 (8)
Alcohol use during pregnancy — no. (%)	1 (1)	1 (1)
Race — no. (%)‡		
White	87 (89)	88 (90)
Asian	3 (3)	3 (3)
Black	2 (2)	2 (2)
Other	6 (6)	5 (5)
Findings on ultrasonography at randomization		
Median quotient of observed-to-expected lung-to-head ratios (IQR) — %§	30.9 (28.0–34.0)	31.0 (28.0–34.5)
Intrathoracic liver herniation — no. (%)	79 (81)	78 (80)
Median deepest vertical pocket of amniotic fluid (IQR) — cm	6.0 (5.0–7.6)	6.4 (5.5–7.7)
Median cervical length (IQR) — mm	37 (33–40)	36 (31–40)
Placental position — no. (%)		
Anterior	50 (51)	47 (48)
Posterior	43 (44)	47 (48)
Fundal	5 (5)	4 (4)

* FETO denotes fetoscopic endoluminal tracheal occlusion, and IQR interquartile range.

† The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters.

‡ Race was reported by the participants.

§ The quotient of observed-to-expected lung-to-head ratios is calculated as the ratio of the ultrasonographic measurement of the observed lung area to head circumference (measured on ultrasonography) divided by the ratio of that which would be expected in a healthy fetus of the same gestational age.

Table 2. Outcomes According to Trial Group in the Intention-to-Treat Population.*

Outcome	FETO Group (N=98)	Expectant Care Group (N=98)	Relative Risk (95% CI)	Difference (95% CI)†
Primary outcomes — no. (%)				
Survival to discharge from NICU	62 (63)	49 (50)	1.27 (0.99 to 1.63)	13 (-1 to 28)‡
Survival to 6 mo without oxygen supplementation	53 (54)	43 (44)	1.23 (0.93 to 1.65)	10 (-4 to 25)
Secondary and exploratory outcomes				
Postnatal survival — no. (%)				
To 28 days§	67 (68)	56 (57)	1.20 (0.96 to 1.50)	11 (-2 to 25)
To 56 days§	65 (66)	54 (55)	1.20 (0.96 to 1.52)	11 (-3 to 26)
To 6 mo	61 (62)	49 (50)	1.24 (0.97 to 1.61)	12 (-2 to 27)
Preterm, prelabor rupture of membranes¶				
Median gestational age (IQR) — wk§	34.0 (33.0 to 35.0)	34.6 (31.4 to 35.6)		0.6 (-2.0 to 3.3)
Rupture of membranes at <37 wk — no./total no. (%)§	43/97 (44)	11/93 (12)**	3.79 (2.13 to 6.91)	33 (21 to 46)
Rupture of membranes at <34 wk — no./total no. (%)§	21/97 (22)	5/93 (5)**	4.07 (1.68 to 10.1)	16 (6 to 27)
Gestational age at birth¶¶				
Median gestational age (IQR) — wk	35.9 (34.3 to 37.9)	38.1 (37.0 to 38.9)		-2.3 (-3.0 to -1.5)
<37 wk — no./total no. (%)	62/97 (64)	21/94 (22)	2.86 (1.94 to 4.34)	42 (29 to 56)
<34 wk — no./total no. (%)	19/97 (20)	7/94 (7)	2.63 (1.20 to 5.89)	12 (2 to 23)
<32 wk — no./total no. (%)	6/97 (6)	3/94 (3)	1.94 (0.55 to 6.93)	3 (-5 to 10)
Placental abruption — no./total no. (%)§§	0/97	0/94	NC††	0 (-5 to 5)
Neonatal outcomes in live births¶¶				
Median birth weight (IQR) — g§	2500 (2200 to 2855)	2945 (2500 to 3292)		-445 (-635 to -260)
Neonatal repair of defect — no./total no. (%)	81/97 (84)	70/94 (74)	1.12 (0.97 to 1.31)	9 (-3 to 21)

Use of prosthetic patch for repair — no./total no. (%)	67/81 (83)	50/70 (71)	1.16 (0.97 to 1.41)	11 (-3 to 26)
Median time to repair of defect (IQR) — days	3 (2 to 6)	3 (2 to 5)		0 (0 to 2)
ECMO — no./total no. (%)	20/97 (21)	19/94 (20)	1.02 (0.59 to 1.78)	0 (-12 to 13)

* Data are for the overall intention-to-treat population unless otherwise specified. The between-group differences may not be the expected values because of rounding. ECMO denotes extracorporeal membrane oxygenation, NC not calculated, and NICU neonatal intensive care unit.

† Differences were calculated as the absolute difference in percentages (expressed in percentage points) for dichotomous data or as the difference in medians for continuous data.

‡ P = 0.06 for the comparison between the FETO group and the expectant care group.

§ This was an exploratory outcome.

¶ One spontaneous fetal death in each group and three terminated pregnancies in the expectant care group were excluded.

|| In addition to the one spontaneous fetal death and three terminated pregnancies, data on two additional pregnancies were missing. For the calculation of relative risk and the difference in medians, missing values were addressed according to the protocol.

** In addition to the one spontaneous fetal death and three terminated pregnancies, data on one additional pregnancy were missing. For the calculation of relative risk and the difference in percentages, missing values were addressed according to the protocol.

†† The relative risk was not calculated because both percentages equal 0.

the balloon was successfully inserted (60%), the balloon was removed as originally planned, whereas in 35 women (39%), balloon removal was undertaken earlier, mainly because the women went into spontaneous labor or had preterm, prelabor rupture of membranes; in 1 woman (1%), no removal was attempted because spontaneous deflation occurred. Balloon removal was mostly performed by means of fetoscopy (in 98% of elective removals and 69% of emergency procedures). In all but 1 fetus, reversal of occlusion was successful.

PRIMARY OUTCOMES

The trial was not stopped early for superiority. The percentages of infants who survived to discharge from the NICU were 63% (62 of 98 infants) in the FETO group and 50% (49 of 98 infants) in the expectant care group (relative risk, 1.27; 95% confidence interval [CI], 0.99 to 1.63; two-sided P = 0.06) (Table 2). The percentages of infants who survived without oxygen supplementation at 6 months of age were 54% (53 of 98 infants) and 44% (43 of 98 infants), respectively (relative risk, 1.23; 95% CI, 0.93 to 1.65) (Table 2). The per-protocol analysis yielded similar results with respect to survival to discharge from the NICU (relative risk, 1.23; 95% CI, 0.96 to 1.59) and survival at 6 months of age without oxygen supplementation (relative risk, 1.21; 95% CI, 0.90 to 1.62).

SECONDARY AND EXPLORATORY OUTCOMES

Two unexplained fetal deaths occurred, one in the FETO group at 37 weeks 2 days of gestation and one in the expectant care group at 36 weeks 2 days of gestation. The incidence of preterm, prelabor rupture of membranes was 44% in the FETO group and 12% in the expectant care group (relative risk, 3.79; 95% CI, 2.13 to 6.91); the respective incidences of preterm birth were 64% and 22% (relative risk, 2.86; 95% CI, 1.94 to 4.34). The median gestational age at delivery was approximately 2 weeks earlier in the FETO group than in the expectant care group (Table 2).

Results in infants who survived to NICU discharge are shown in Table S5; these results are presented descriptively. However, there were no obvious between-group differences in the duration of NICU stay or neonatal complications. The outcomes and characteristics of 183 eligible participants who did not undergo randomization are shown in Figure S1.

ADVERSE EVENTS

Serious and other adverse events are reported in Table 3. Preterm, prelabor rupture of membranes and preterm delivery were the most frequent adverse events in the FETO group. No cases of placental abruption occurred in either group, and no intraoperative complications occurred in the FETO group.

There were two problematic balloon removals. One infant could not be resuscitated after an emergency attempted removal of the balloon with an endoscope at the time of delivery while the umbilical cord still connected the infant to the placenta. The balloon, which was thought to have been punctured, was found intact within the trachea at the postmortem examination. In retrospect, the airways had been explored under

direct vision, so the operator had less control of the procedure and less adequate assessment of the position and status of the balloon than would have been provided with endoscopic vision. In one other infant, postnatal removal of the balloon took up to 3 minutes from the time of birth until intubation.

In the FETO group, tracheomalacia was diagnosed in one infant at 2 months of age and tracheomalacia was suspected in another infant. Details are provided in Table 3.

DISCUSSION

In this multicenter, randomized trial involving woman carrying singleton fetuses with isolated moderate congenital diaphragmatic hernia on

Table 3. Adverse Events in the Safety Population.*

Event	FETO Group (N=91)†	Expectant Care Group (N=95)‡
	number/total number (%)	
Serious adverse events		
Fetal death		
<24 hr after FETO	0/91	NA
Any time during pregnancy§	1/91 (1)	1/95 (1)
Placental abruption		
<24 hr after FETO	0/91	NA
Any time during pregnancy	0/91	0/95
Lengthy balloon removal procedure¶	1/91 (1)	NA
Severe preeclampsia	1/91 (1)	0/95
Chorioamnionitis	1/91 (1)	1/95 (1)
Abnormal cardiotocographic findings before labor	3/91 (3)	2/95 (2)
Intrauterine growth restriction	2/91 (2)	3/95 (3)
Preterm, prelabor rupture of membranes <37 wk	42/91 (46)	11/94 (12)
Delivery <37 wk	60/91 (66)	22/95 (23)
Neonatal death due to failure of balloon removal	1/91 (1)	NA
Perinatal asphyxia, umbilical pH <7.00	0/70	2/63 (3)
ECMO	18/91 (20)	19/95 (20)
Conditions in infants who survived to discharge		
Bronchopulmonary dysplasia	37/57 (65)	32/49 (65)
Pulmonary hypertension	42/57 (74)	33/49 (67)
Periventricular leukomalacia	3/57 (5)	1/49 (2)
Sepsis	19/57 (33)	17/49 (35)
Necrotizing enterocolitis	2/57 (4)	0/49
Intraventricular hemorrhage >grade III	0/57	0/49
Retinopathy of prematurity	0/57	0/49
Death		
Neonatal, <28 days	28/91 (31)	38/95 (40)
Between 28 days and 6 mo	6/91 (7)	7/95 (7)
Tracheomalacia or tracheal changes**	2/91 (2)	NA

Table 3. (Continued.)

Event	FETO Group (N=91) [†]	Expectant Care Group (N=95) [‡]
	number/total number (%)	
Other adverse events		
Fetal hydrops	0/91	1/95 (1)
Bilateral fetal hydrothorax	1/91 (1)	0/95
Chorioamniotic membrane separation	23/88 (26)	NM
Vaginal bleeding	3/91 (3)	0/95
Bleeding resulting from trocar insertion during fetoscopy	5/91 (5)	NA
Polyhydramnios first manifesting at follow-up ultrasonographic examination	22/88 (25)	NM
Gastroesophageal reflux in infants who survived to discharge	30/55 (55)	19/39 (49)

* The safety population included all the participants who underwent randomization and who effectively received their assigned prenatal treatment (see the statistical analysis plan, which is available with the protocol). NA denotes not applicable, and NM not measured.

[†] This group includes the 98 participants who were randomly assigned to undergo FETO minus 7 participants who did not have a surgical procedure: 4 participants decided not to undergo FETO, and the other 3 did not undergo FETO owing to ruptured membranes (1 participant), a very short cervix (1 participant), and poor fetal position precluding an attempt to insert the trocar (1 participant).

[‡] This group includes the 98 participants who were randomly assigned to receive expectant care minus 3 participants who opted for termination of pregnancy.

[§] In the FETO group, a postmortem examination did not identify any plausible cause for the intrauterine fetal death. In the expectant care group, a placental examination showed a massive thrombosis with complete vascular occlusion in one of the umbilical arteries. Examination of the mother's blood showed a low level of protein S and low positivity for lupus anticoagulant. The data and safety monitoring board considered these findings insufficient to determine causation and categorized the death as "unexplained."

[¶] Because of unavailability of the maternal fetal medicine specialist, balloon puncture was performed after vaginal birth by the attending neonatologist. The neonatal umbilical artery pH was 7.34, and conventional mechanical ventilation was promptly initiated. The infant died of acute bilateral pneumonia at 23 days.

^{||} The occurrence or absence of anticipated adverse events was indicated in check boxes (yes or no). Any other event that was not anticipated could be reported in a free-text field. For the events indicated in check boxes, the denominator takes into account missing values.

** Tracheomalacia was suspected in 1 infant who was discharged without respiratory support. Inflammation and scarring were observed during bronchoscopy at the time of fundoplication at 5 months of age; follow-up bronchoscopy at 10.5 months of age showed that these conditions had improved. The infant had known reflux, which was considered to be a potential cause of the findings, and thus the infant was considered to have possible tracheomalacia.

the left side, the chance of survival of infants to discharge from the NICU or survival without oxygen supplementation at 6 months of age was not significantly greater with prenatal intervention with FETO at 30 to 32 weeks of gestation than with expectant care. The confidence interval is compatible with an increase in survival to discharge from the NICU that is 1 percentage point lower to 63% percentage points higher in the FETO group than in the expectant care group. The risk of preterm, prelabor rupture of membranes was 3.8 times as high and the risk of preterm birth was 2.9 times as high in the FETO group as in the expectant care group. No other serious complications occurred in the women, and there were no obvious between-group differences in the duration of neonatal intensive care or the duration of ventilatory sup-

port in the infants. However, the trial was not powered for these or other complications associated with prematurity.

The results in the expectant care group in this trial are consistent with those in contemporary nonintervention studies involving prenatally diagnosed congenital diaphragmatic hernia,²⁶ with similar fetal lung measurement methods and protocols for postnatal care.^{27,28} Little was known before this trial about outcomes of FETO in fetuses with moderate pulmonary hypoplasia, because nearly all previous studies were limited to fetuses with severe pulmonary hypoplasia.^{14,15,29}

A companion article now published in the *Journal* describes a randomized trial involving fetuses with isolated congenital diaphragmatic hernia and severe pulmonary hypoplasia on the left side.³⁰ In that trial, which we carried out in

parallel to this trial and in many of the same centers, we found that 40% of the infants of mothers assigned to FETO, as compared with 15% of those in the expectant care group, survived to discharge from the NICU (relative risk, 2.67; 95% CI, 1.22 to 6.11).³⁰ In addition to the between-trial difference in the severity of congenital diaphragmatic hernia, the timing of FETO also differed (i.e., 27 to 29 weeks of gestation in the trial of severe pulmonary hypoplasia and 30 to 32 weeks of gestation in this trial). It is possible that the delay in tracheal occlusion contributed to the lack of significant improvement in survival in the current trial. The main reason for such delay was to minimize the risk of procedure-related preterm, prelabor rupture of membranes and very preterm birth in infants with moderate disease, given the considerably lower risk of death among these infants than among those with severe disease and the serious consequences of extreme prematurity associated with congenital diaphragmatic hernia.³¹

A limitation of the current trial is the long time period required to complete it,³² during which the protocols for postnatal care of congenital diaphragmatic hernia may have changed³³⁻³⁵; however, this would apply to both trial groups. Data are not available on medium-term or long-term outcomes, and the trial was not powered to inform uncommon fetal, pediatric, and maternal complications. It is difficult to compare our results, which were obtained in fetuses with prenatally diagnosed congenital diaphragmatic hernia, with those reported by centers that have a different case mix (i.e., those that typically care for women referred late in pregnancy or infants transferred after birth).^{33,34} In addition, although the investigators were aware of the treatment group assignments, we do not think this would have affected the care of the patients. Also, the performance of FETO requires a wide range of skills, from the ability to perform ultrasound-guided needle procedures to expertise in advanced fetoscopy, as well as the round-the-clock

availability of staff members with those skills, and our trial centers had high caseloads. Therefore, the findings should not be generalized to less experienced centers.²³

Future studies are needed to assess potential strategies to reduce FETO-associated complications — such as the use of thinner fetoscopic instruments to reduce the risk of preterm, prelabor rupture of membranes,^{36,37} ultrasound-guided puncture rather than fetoscopy for removal of the balloon,²³ and the use of a balloon with a magnetic valve that can be opened noninvasively.^{38,39} Data are also lacking to assess whether a longer occlusion period would result in additional lung growth.^{16,40} Finally, a post hoc analysis of the combined data from this trial and the companion trial involving fetuses with severe pulmonary hypoplasia,³⁰ with the use of the quotient of the observed-to-expected lung-to-head ratios as a continuous variable, may help to inform inclusion criteria for further studies involving fetuses with moderate pulmonary hypoplasia.

This randomized trial involving fetuses with isolated moderate congenital diaphragmatic hernia on the left side did not show a significant increase in survival of infants to NICU discharge or a reduction in the need for oxygen supplementation at 6 months of life among infants assigned to FETO. FETO resulted in increased risks of preterm, prelabor rupture of membranes and preterm birth.

Supported by a grant (“EuroSTEC” FP6-LIFESCIHEALTH CT 2006-37409, to Dr. Deprest) from the European Commission for the initial trial setup; a grant (C32/17/054, to Dr. Deprest) from KU Leuven; grants (WT101957) from the Wellcome Trust and (NS/A000027/1) from the Engineering and Physical Sciences Research Council of the United Kingdom for the Image-Guided Intrauterine Minimally Invasive Fetal Diagnosis and Therapy study (both to Drs. Deprest and Nicolaides); and grants (to Dr. Benachi) from the Unité de Recherche Clinique Paris Assistance Publique–Hôpitaux de Paris Center, Université de Paris Necker–Cochin, and from Assistance Publique–Hôpitaux de Paris for data management and monitoring.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

A data sharing statement provided by the authors is available with the full text of this article at NEJM.org.

REFERENCES

1. Ameis D, Khoshgoo N, Keijzer R. Abnormal lung development in congenital diaphragmatic hernia. *Semin Pediatr Surg* 2017;26:123-8.
2. Harting MT, Lally KP. The Congenital Diaphragmatic Hernia Study Group registry update. *Semin Fetal Neonatal Med* 2014;19:370-5.
3. Section on Surgery and the Committee on Fetus and Newborn. Postdischarge follow-up of infants with congenital diaphragmatic hernia. *Pediatrics* 2008;121:627-32.

4. Jani J, Nicolaides KH, Keller RL, et al. Observed to expected lung area to head circumference ratio in the prediction of survival in fetuses with isolated diaphragmatic hernia. *Ultrasound Obstet Gynecol* 2007;30:67-71.
5. Dekoninck P, Gratacos E, Van Mieghem T, et al. Results of fetal endoscopic tracheal occlusion for congenital diaphragmatic hernia and the set up of the randomized controlled TOTAL trial. *Early Hum Dev* 2011;87:619-24.
6. Lusk LA, Wai KC, Moon-Grady AJ, Basta AM, Filly R, Keller RL. Fetal ultrasound markers of severity predict resolution of pulmonary hypertension in congenital diaphragmatic hernia. *Am J Obstet Gynecol* 2015;213(2):216.e1-8.
7. Jani JC, Benachi A, Nicolaides KH, et al. Prenatal prediction of neonatal morbidity in survivors with congenital diaphragmatic hernia: a multicenter study. *Ultrasound Obstet Gynecol* 2009;33:64-9.
8. Doné E, Gratacos E, Nicolaides KH, et al. Predictors of neonatal morbidity in fetuses with severe isolated congenital diaphragmatic hernia undergoing fetoscopic tracheal occlusion. *Ultrasound Obstet Gynecol* 2013;42:77-83.
9. Wilson JM, DiFiore JW, Peters CA. Experimental fetal tracheal ligation prevents the pulmonary hypoplasia associated with fetal nephrectomy: possible application for congenital diaphragmatic hernia. *J Pediatr Surg* 1993;28:1433-9.
10. Khan PA, Cloutier M, Piedboeuf B. Tracheal occlusion: a review of obstructing fetal lungs to make them grow and mature. *Am J Med Genet C Semin Med Genet* 2007;145C:125-38.
11. Flageole H, Evrard VA, Piedboeuf B, Laberge JM, Lerut TE, Deprest JA. The plug-unplug sequence: an important step to achieve type II pneumocyte maturation in the fetal lamb model. *J Pediatr Surg* 1998;33:299-303.
12. Deprest J, Gratacos E, Nicolaides KH. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia: evolution of a technique and preliminary results. *Ultrasound Obstet Gynecol* 2004;24:121-6.
13. Jani JC, Nicolaides KH, Gratacos E, et al. Severe diaphragmatic hernia treated by fetal endoscopic tracheal occlusion. *Ultrasound Obstet Gynecol* 2009;34:304-10.
14. Al-Maary J, Eastwood MP, Russo FM, Deprest JA, Keijzer R. Fetal tracheal occlusion for severe pulmonary hypoplasia in isolated congenital diaphragmatic hernia: a systematic review and meta-analysis of survival. *Ann Surg* 2016;264:929-33.
15. Araujo Júnior E, Tonni G, Martins WP, Ruano R. Procedure-related complications and survival following fetoscopic endotracheal occlusion (FETO) for severe congenital diaphragmatic hernia: systematic review and meta-analysis in the FETO era. *Eur J Pediatr Surg* 2017;27:297-305.
16. Nawapun K, Eastwood MP, Diaz-Cobos D, et al. In vivo evidence by magnetic resonance volumetry of a gestational age dependent response to tracheal occlusion for congenital diaphragmatic hernia. *Prenat Diagn* 2015;35:1048-56.
17. Jani JC, Nicolaides KH, Gratacos E, Vandecruys H, Deprest JA, FETO Task Group. Fetal lung-to-head ratio in the prediction of survival in severe left-sided diaphragmatic hernia treated by fetal endoscopic tracheal occlusion (FETO). *Am J Obstet Gynecol* 2006;195:1646-50.
18. Reiss I, Schaible T, van den Hout L, et al. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium consensus. *Neonatology* 2010;98:354-64.
19. Snoek KG, Reiss IK, Greenough A, et al. Standardized postnatal management of infants with congenital diaphragmatic hernia in Europe: the CDH EURO Consortium consensus — 2015 update. *Neonatology* 2016;110:66-74.
20. Engels AC, DeKoninck P, van der Merwe JL, et al. Does website-based information add any value in counseling mothers expecting a baby with severe congenital diaphragmatic hernia? *Prenat Diagn* 2013;33:1027-32.
21. TOTAL trial (<https://totaltrial.eu/>).
22. Van der Veen L, Russo FM, De Catte L, et al. Fetoscopic endoluminal tracheal occlusion and reestablishment of fetal airways for congenital diaphragmatic hernia. *Gynecol Surg* 2018;15:9.
23. Jiménez JA, Eixarch E, DeKoninck P, et al. Balloon removal after fetoscopic endoluminal tracheal occlusion for congenital diaphragmatic hernia. *Am J Obstet Gynecol* 2017;217(1):78.e1-78.e11.
24. Bancalari E, Claire N. Definitions and diagnostic criteria for bronchopulmonary dysplasia. *Semin Perinatol* 2006;30:164-70.
25. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. *Biometrics* 1979;35:549-56.
26. Alfaraj MA, Shah PS, Bohn D, et al. Congenital diaphragmatic hernia: lung-to-head ratio and lung volume for prediction of outcome. *Am J Obstet Gynecol* 2011;205(1):43.e1-8.
27. Snoek KG, Capolupo I, van Rosmalen J, et al. Conventional mechanical ventilation versus high-frequency oscillatory ventilation for congenital diaphragmatic hernia: a randomized clinical trial (The VICI-trial). *Ann Surg* 2016;263:867-74.
28. Snoek KG, Peters NCJ, van Rosmalen J, et al. The validity of the observed-to-expected lung-to-head ratio in congenital diaphragmatic hernia in an era of standardized neonatal treatment; a multicenter study. *Prenat Diagn* 2017;37:658-65.
29. Grivell RM, Andersen C, Dodd JM. Prenatal interventions for congenital diaphragmatic hernia for improving outcomes. *Cochrane Database Syst Rev* 2015;11(11):CD008925.
30. Deprest JA, Nicolaides KH, Benachi A, et al. Randomized trial of fetal surgery for severe left diaphragmatic hernia. *N Engl J Med* 2021;385:107-18.
31. Bouchghoul H, Dumery G, Russo FM, et al. Optimal gestational age at delivery for congenital diaphragmatic hernia. *Ultrasound Obstet Gynecol* 2020 July 1 (Epub ahead of print).
32. Basurto D, Russo FM, Van der Veen L, et al. Prenatal diagnosis and management of congenital diaphragmatic hernia. *Best Pract Res Clin Obstet Gynaecol* 2019;58:93-106.
33. Snoek KG, Greenough A, van Rosmalen J, et al. Congenital diaphragmatic hernia: 10-year evaluation of survival, extracorporeal membrane oxygenation, and fetoscopic endotracheal occlusion in four high-volume centres. *Neonatology* 2018;113:63-8.
34. van den Hout L, Schaible T, Cohen-Overbeek TE, et al. Actual outcome in infants with congenital diaphragmatic hernia: the role of a standardized postnatal treatment protocol. *Fetal Diagn Ther* 2011;29:55-63.
35. Deprest J. Prenatal treatment of severe congenital diaphragmatic hernia: there is still medical equipoise. *Ultrasound Obstet Gynecol* 2020;56:493-7.
36. Ruano R, Duarte SA, Pimenta EJ, et al. Comparison between fetal endoscopic tracheal occlusion using a 1.0-mm fetoscope and prenatal expectant management in severe congenital diaphragmatic hernia. *Fetal Diagn Ther* 2011;29:64-70.
37. Mari G, Deprest J, Schenone M, et al. A novel translational model of percutaneous fetoscopic endoluminal tracheal occlusion — baboons (*Papio spp.*). *Fetal Diagn Ther* 2014;35:92-100.
38. Basurto D, Sananès N, Verbeken E, et al. New device permitting non-invasive reversal of fetal endoscopic tracheal occlusion: ex-vivo and in-vivo study. *Ultrasound Obstet Gynecol* 2020;56:522-31.
39. Basurto D, Sananès N, Bleaser T, et al. Safety and efficacy of smart tracheal occlusion device in diaphragmatic hernia lamb model. *Ultrasound Obstet Gynecol* 2021;57:105-12.
40. Cannie MM, Jani JC, De Keyser F, Allegaert K, Dymarkowski S, Deprest J. Evidence and patterns in lung response after fetal tracheal occlusion: clinical controlled study. *Radiology* 2009;252:526-33.

Copyright © 2021 Massachusetts Medical Society.

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Deprest JA, Benachi A, Gratacos E, et al. Randomized trial of fetal surgery for moderate left diaphragmatic hernia. *N Engl J Med* 2021;384:119-29. DOI: 10.1056/NEJMoa2026983

TOTAL trial for moderate hypoplasia

Supplementary appendix

Table of contents of the appendix		
List of investigators		2
Figure S1	Outcomes of eligible non-participants	6
Supplementary Table S1	Alphabetical list of FETO and neonatal management centers	7
Supplementary Table S2	List of reported outcomes and safety endpoints	9
Supplementary Table S3	Associated anomalies diagnosed after randomization	12
Supplementary Table S4	Operative outcomes in patients in the FETO arm	13
Supplementary Table S5	Secondary neonatal outcomes in survivors to discharge	14
Supplementary Table S6	Interim analyses	15
Supplementary Table S7	Case load and historical outcomes for postnatal management centers	16

List of investigators

Principal Investigators

Jan A Deprest¹ M.D. Ph.D., Alexandra Benachi² M.D. Ph.D., Eduard Gratacos³ M.D. Ph.D., Kypros H Nicolaides⁴ M.D., Christoph Berg⁵ M.D. Ph.D., Nicola Persico⁶ M.D. Ph.D., Michael Belfort⁷ M.D. Ph.D., Glenn J. Gardener⁸ M.D. Ph.D., Yves Ville⁹ M.D. Ph.D., Anthony Johnson¹⁰ M.D., Francesco Morini¹¹ M.D. Ph.D., Mirosław Wielgos¹² M.D. Ph.D., Ben Van Calster¹ Ph.D., Philip LJ DeKoninck^{1, 17} M.D. Ph.D.

Data Monitoring and Safety Committee and data managers

Paul Lewi †¹, Ph.D., Tim Van Mieghem^{1,13} M.D. Ph.D., Francesca Russo¹ M.D. Ph.D., Hugo Devlieger¹ M.D. Ph.D., Michael Harrison¹⁴ M.D. Ph.D., Francois I Luks¹⁵ M.D. Ph.D., Angélique Rezer¹ LL.M., Kris Dierickx¹ Ph.D., Beverley Power¹⁶

External committee drafting neonatal guidelines

Dick Tibboel¹⁷ M.D. Ph.D., Thomas Schaible¹⁸ M.D. Ph.D., Laurent Storme¹⁹ M.D. Ph.D.

Affiliations

¹ The University Hospitals KU Leuven, Leuven, Belgium; ² Hospital Antoine Bécère, Université Paris Saclay, Clamart, France; ³ Hospital Clinic and Sant Joan de Deu, Barcelona, Spain; ⁴ King's College Hospital, London, UK; ⁵ University Hospital Bonn, Bonn, Germany; ⁶ Hospital Maggiore Policlinico, Milano, Italy; ⁷ Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA; ⁸ Mater Mother's Hospital, Brisbane, Australia; ⁹ Hospital Necker, Paris, France; ¹⁰ Children's Hermann Memorial Hospital, Houston, TX, USA; ¹¹ Bambino Gesù Children's Hospital, Rome, Italy; ¹² Medical University of Warsaw, Warsaw, Poland; ¹³ Mount Sinai Hospital, Toronto, ON, Canada; ¹⁴ University of California at San Francisco, CA, USA; ¹⁵ Hasbro Children's Hospital, Providence, RI, USA; ¹⁶ C.D.H. UK Parent Organization, London, UK; ¹⁷ Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands; ¹⁸ Mannheim University Hospital, Mannheim, Germany; ¹⁹ University Medical Center Lille, Lille, France.

† Prof P. Lewi deceased during the trial

Other TOTAL trial for moderate CDH collaborators


The University Hospitals KU Leuven, Leuven, Belgium – Liesbeth Lewi M.D. Ph.D., Roland Devlieger M.D. Ph.D., Anne Debeer, M.D. Ph.D., Herbert De Caluwe M.D. Ph.D.; **Hôpital Bicêtre, Paris France** – Anne-Gael Cordier M.D. Ph.D., Nolwenn Le Sache M.D., Virginie Fouquet M.D.; **Brugmann Hospital, Brussels, Belgium** – Jacques Jani M.D. Ph.D.; **Hospital**

Clinic/Hospital Sant Joan de Deu, Barcelona – Josep Maria Martinez M.D., Olga Gomez M.D., Rogelio Cruz-Martinez M.D., Africa Pertierra M.D.; **King's College Hospital, London, UK** - Ramona Cazacu M.D., Theodore Dassios M.D., Shailesh Patel M.D., Ewelina Litwinska M.D.; **Universitätsklinikum Bonn, Bonn, Germany** – Brigitte Strizek M.D., Andreas Müller M.D., Andreas Heydweiller M.D.; **Ospedale Maggiore Policlinico, Milan, Italy** – Isabella Fabiatti M.D., Fabio Mosca M.D., Ernesto Leva M.D.; **Baylor College of Medicine/Texas Children's Hospital, Houston, USA** – Alireza A. Shamshirsaz M.D., Joseph A. Garcia-Prats M.D., Timothy Lee M.D.; **Mater Mothers Hospital, Brisbane, Australia** – Scott Petersen M.D., Lucy Cooke M.D., Craig McBride M.D.; **Hôpital Necker – Enfants Malades, Paris, France** – Julien Stirneman M.D., Elsa Kermorvant-Duchemin M.D., Naziha Ken-Dunlop M.D.; **University of Texas Health Science Center / Children's Memorial Hermann, Houston, USA** – Mary Austin M.D., Suzanne M. Lopez M.D., Kuojen Tsao M.D.; **Bambino Gesù Children's Hospital, Rome, Italy** – Anita Romiti M.D., Irma Capolupo M.D., Laura Valfre M.D.; **1st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland** – Przemyslaw Kosinski M.D., Pawel Krajewski M.D., Andrzej Kaminski M.D.; **Radboudumc/Amalia Children's Hospital, Nijmegen, The Netherlands** – Mallory Woiski M.D., Willem P. de Boode M.D., Horst Daniels-Scharbatke M.D.; **Hôpital Robert Debré, Paris, France** – Jonathan Rosenblatt M.D.; Michael Levy M.D., Elisabeth Carricaburu M.D.; **Hôpital Bretonneau, Tours, France** – Franck Perrotin M.D., Antoine Bouissou M.D., Hubert Lardy M.D.; **Erasmus MC University Medical Center, Rotterdam, The Netherlands** – Alex J. Eggink M.D., Rene M.H. Wijnen M.D.; **CHU de Bordeaux, Bordeaux, France** – Loic Sentilhes M.D., Olivier Brissaud M.D., Frederic Lavrand M.D.; **LKH-Universitäts Klinikum Graz, Graz, Austria** – Philipp Klaritsch M.D., Berndt Urlesberger M.D., Holger Till M.D.; **Hôpital Trousseau, Paris, France** – Jean-Marie Jouannic M.D., Julia Guilbert M.D., Sabine Irtan, M.D.; **CHU Amiens, Amiens, France** – Arthur Foulon M.D., Pierre Tourneux M.D., Philippe Buisson M.D.; **Saint Luc UCL, Brussels, Belgium** – Jean-Marc Biard M.D., Catheline Hocq M.D., Catherine De Magnée M.D.; **CHU Caen, Caen, France** – Guillaume Benoist M.D., Valerie Datin-Dorriere M.D.; Thierry Petit M.D.; **CHU de Dijon, Dijon, France** – Thierry Rousseau M.D., Stephanie Litzler-Renault M.D., Emmanuel Sapin M.D.; **Medical University of Gdansk, Gdansk, Poland** – Krzysztof Preis M.D., Iwona Janczewska M.D., Andrzej Golebiewski M.D.; **CHRU Lille, Lille, France** – Veronique Houfflin-Debarge M.D., Dyuti Sharma M.D.; **Gregorio Maranon Hospital, Madrid, Spain** – Eugenia Antolin Alvarado M.D., Belen Bernardo Atienza M.D., Juan Carlos de Agustín Asensio M.D.; **The Royal Women's Hospital, Melbourne, Australia** – Stefan Kane M.D., Rodney Hunt M.D.; **Women's and Children's Hospital, Adelaide, Australia** – Peter Muller M.D., Jodie Dodd M.D., Catherine Cord-Udy M.D.; **University of Michigan Health System, Ann Arbor, USA** – Erin E. Perrone M.D.; **Chelsea and Westminster Hospital NHS Foundation Trust, London, UK** – Makrina

Savvidou M.D., Shu-ling Chuang M.D., Simon Clarke M.D.; **CHU Clermont-Ferrand, Clermont-Ferrand, France** – Amelie Delabaere M.D., Karen Coste M.D., Maguelonne Pons M.D.; **Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany** – Kurt Hecher M.D. Ph.D.; **St George's University Hospitals, London, UK** – Basky Thilaganathan M.D. Ph.D., Nigel Kennea M.D., Bruce Okoye M.D.; **University Hospital Mannheim, Mannheim, Germany** – Katrin Zahn M.D., Christiane Otto M.D.; **CHU Montpellier, Montpellier, France** – Florent Fuchs M.D., Odile Pidoux M.D., Dominique Forgues M.D.; **CHU Nancy, Nancy, France** – Alexis Maatouk M.D., Mahmoud Rouabah M.D., Jean-Louis Lemelle M.D.; **The Institute for the Care of Mother and Child, Prague, Czech Republic** – Ladislav Krofta M.D., Zbynek Stranak M.D., Michal Rygl M.D.; **CHU Rennes, Rennes, France** – Gwenaelle Le Bouar M.D., Alain Beuchée M.D., Alexis Arnaud M.D.; **CHU Saint Etienne, Saint Etienne, France** – Marie-Noelle Varlet M.D., Caroline Paricio M.D., Fabienne Prieur M.D.; **St Olavs Hospital, Trondheim, Norwich** – Brigitte Heiberg Kahrs M.D., Øystein Drivenes M.D.; **University Hospital Zurich, Zurich, Suisse** – Nicole Ochsenbein-Kölble M.D., Ueli Möhrlen M.D.; **Medway Maritime Hospitals, Gillingham, UK** – Ranjit Akolekar M.D., Shakuntala Kalla M.D.; **UZ Gent, Gent, Belgium** – Elke Sleurs M.D.; **Royal Free London NHS Foundation Trust, London, UK** – Rezan Abdul-Kadir M.D.; **Baylor College of Medicine, Houston, USA** – Karolina Adam M.D.; **Hospital Universitario de Canarias, Tenerife, Spain** – Margarita Alvarez de la Rosa M.D.; **Covenant Medical Group, Lubbock, USA** – Bill Atkinson M.D.; **Klinikum Kreuzschwestern Wels, Wels, Austria** – Alfred Bacherer M.D.; **University of South Alabama, Mobile, USA** – Susan L. Baker M.D.; **Hôpital Arnaud de Villeneuve, Montpellier, France** – Laetitia Begue M.D.; **CHU Angers, Angers, France** – Florence Biquard M.D.; **Regional Perinatal Group, Willis-Kinghton Health System, Shreveport, Louisiana, USA** – Christian Briery, M.D.; **Fetal Medicine Unit, Central Manchester University Hospitals NHS Foundation Trust, UK** – Phil Bullen M.D.; **Fundació Hospital Asil de Granollers, Barcelona, Spain** – Maria José Canto Rivera M.D.; **CHR Citadelle, CHU Liège, Belgium** – Frederic Chantraine M.D.; **Hull and East Yorkshire Hospitals NHS Trust, Hull, UK** – Anne Marie Coady M.D.; **Limoges Regional University Hospitals, Limoges, France** – Perrine Coste-Mazeau M.D.; **Hospital Universitari Dexeus, Barcelona, Spain** – Mónica Echevarria Telleria M.D.; **Hospital 12 de Octubre-IMAS 12, Madrid, Spain** – Alberto Galindo Izquierdo M.D.; **University Hospital Cologne, Cologne, Germany** – Ingo Gottschalk M.D.; **Piñon Perinatal, Albuquerque, USA** – Timothy J Hurley M.D.; **The John Radcliffe Hospital Oxford, Oxford, UK** – Lawrence Impey M.D.; **UZ Antwerpen, Antwerpen, Belgium** – Yves Jacquemyn M.D.; **University of Texas Medical Branch, Galveston, Texas, USA** – Sangeeta Jain M.D.; **Leiden University Medical Center, Leiden, The Netherlands** – Frans JCM Klumper M.D.; **Sheba Medical Center, Tel Hashomer, Israel** – Shlomo Lipitz M.D.; **Hospital Universitari Mutua de Terrassa, Barcelona, Spain** – Eva López Quesada M.D.;

Hospital Clínico Universitario Virgen de la Arrixaca-IMIB, Murcia – Juan Luis Delgado Marin M.D.; **Hospices Civils de Lyon, Lyon, France** – Jérôme Massardier, M.D.; **Center for Assisted Reproduction and Prenatal Diagnosis, Minden, Germany** – Ralf Menkhaus M.D.; **Complejo Hospitalario de Navarra, Pamplona, Spain** – Ana Modroño Blanco M.D.; **University Hospital Jean Minjoz, Besançon, France** – Nicolas Mottet M.D.; **University Hospital Nîmes, Nîmes, France** – Eve Mousty M.D.; **Bambino Gesù Children's Hospital, Rome, Italy** – Antonella Nahom M.D.; **OLV van Lourdes Ziekenhuis, Waregem, Belgium** – Monica Notermans M.D.; **Maastricht UMC, Maastricht, The Netherlands** – Jos Offermans M.D.; **Hospital de la Santa Creu I Sant Pau, Barcelona, Spain** – Juan Parra Roca M.D.; **Stoke Mandeville Hospital, Aylesbury, UK** – Aparna Reddy M.D.; **Hospital Universitario Arnau de Vilanova, Lleida, Spain** – Ricardo Rosell Polo M.D.; **The Leeds Teaching Hospital, Leeds, UK** – Colete Sparey M.D.; **Hospital Universitario Miguel Servet, Zaragoza, Spain** – Mauricio Tajada Duaso M.D.; **CHRU Lille, Lille, France** – Pascal Vaast M.D.; **Ziekenhuis Geel, Geel, Belgium** – Ellen Vercammen M.D.; **University of Milano-Biocca, Monza, Italy** – Patrizia Vergani M.D.

[Click to go to top of document: table of contents](#)

Figure S1: Characteristics and outcomes in eligible non-participants to the study.

	n	O/E LHR	Liver herniation	Lost to follow up	Survival to discharge from NICU
Expectant management	134	31.0 (29.0-34.9)	106/134 (79%)	22/134 (16%)	66/112 (59%)
FETO	2	30.6 (27.0; 34.2)	2/2 (100%)	0/2 (0%)	1/2 (50%)

Continuous variables are reported as medians and interquartile ranges and categorical variables as absolute numbers and percentages.

[Click to go to top of document: table of contents](#)

Supplementary Table S1: Alphabetical list of FETO and their collaborating neonatal management centers

FETO centers	Neonatal management centers
Hospital Clinic, University of Barcelona, Barcelona, Spain	Hospital San Joan de Deu, Barcelona, Spain Gregorio Maranon Hospital, Madrid, Spain CHRU Montpellier, France
Universitätsklinikum Bonn, Germany	Universitätsklinikum Bonn, Germany Klinikum Augsburg, Germany University Hospital Mannheim, Germany Johannes-Wessling-Klinikum, Minden, Germany
Mater Mothers' Hospital, Brisbane, Australia	Mater Mothers' Hospital, Brisbane, Australia Women's and Children's Hospital, Adelaide, Australia The Royal Women's Hospital and The Royal Children's Hospital, Melbourne, Australia
Hôpital Antoine Bécclerè, Clamart, France	Hôpital Bicêtre, Paris, France CHU Amiens, France CHU Caen, France CHU de Bordeaux, France CHU Clermont-Ferrand, France CHU Rennes, France CHU de Dijon, France CHRU Lille, France CHU Nancy, France Hôpital Trousseau, Paris, France Hôpital Robert Debré, Paris, France CHU Saint Etienne, France Hôpital Bretonneau, CHU Tours, France
Baylor College of Medicine/Texas Children's Hospital, Houston, TX, USA	Texas Children's Hospital, Houston, TX, USA University of Michigan Hospital, Ann Arbor, MI, USA Banner Health – University Center Phoenix, Phoenix, AZ, USA
University of Texas Health Science Center / Children's Memorial Hermann, Houston, TX, USA	University of Texas Health Science Center / Children's Memorial Hermann, Houston, TX, USA
University Hospitals Leuven, Belgium	University Hospitals Leuven, Belgium Ospedali Riuniti di Bergamo, Bergamo, Italy UCL St Luc, Brussels, Belgium
	Medical University Hospital, Gdansk, Poland LKH-Universitäts Klinikum Graz, Austria Universitätsklinik Hamburg-Eppendorf, Germany Shaare Zedek Medical Center, Jerusalem, Israel Medical University Hospital, Krakow, Poland Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland Landes Frauen und Kinderklinik, Linz, Austria Institute Polish Mothers Memorial Hospital, Lodz, Poland Neue Frauenklinik, Luzern, Switzerland

	Radboudumc/Amalia Children's Hospital Nijmegen, The Netherlands Clinical Hospital of Padua, Italy The Institute for the Care for Mother and Child, Prague, Czech Republic Erasmus MC, Rotterdam, The Netherlands National Center for Fetal Medicine, Trondheim, Norway Princess Anna Mazowiecka University Hospital, Warsaw, Poland University Hospital Zurich, Switzerland
King's College Hospital, London, UK	King's College Hospital, London, UK Leeds Teaching Hospitals NHS Trust, Leeds, UK John Radcliffe Hospital, Oxford, UK Royal London Hospital, UK Central Manchester University Hospital, UK St. George's Hospital, London, UK Chelsea and Westminster, London, UK
Ospedale Maggiore Policlinico, Milano, Italy	Ospedale Maggiore Policlinico, Milano, Italy Azienda Ospedaliero-Universitaria di Parma, Italy
Hôpital Necker – Enfants Malades, Paris, France	Hôpital Necker – Enfants Malades, Paris, Paris
Ospedale Pediatrico Bambino Gesù, Rome, Italy	Ospedale Pediatrico Bambino Gesù, Rome, Italy
1 st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland	1 st Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland

[Click to go to top of document: table of contents](#)

Supplementary Table S2: List of primary, secondary and exploratory outcome measures, and safety endpoints prospectively collected via the electronic record forms

Primary outcome	Definition
Survival to discharge	Alive at discharge from NICU
Co-primary outcome	
Supplemental oxygen at 6 months of age	Any supplemental oxygen administration
Secondary outcomes	
Change in observed / expected LHR from baseline	(value before balloon removal- baseline value / baseline value)*100 (%)
Change in MRI O/E total lung volume from baseline	(value before balloon removal- baseline value / baseline value)*100 (%)
Grading of oxygen dependency according to Jobe and Bancalari ¹	Measured - at d56 postnatal age or discharge, whichever comes first, for infants born $\geq 32w$ - at 36w postmenstrual age or discharge, whichever comes first, for infants born $< 32w$ Categorized as: - Mild BPD: FiO ₂ 0.21 - Moderate BPD: FiO ₂ 0.22-0.29 - Severe BPD: FiO ₂ > 0.30 , and/or CPAP and/or mechanical ventilation
Pulmonary hypertension	Based on evidence on cardiac ultrasound of predominant unidirectional right to left shunt.
ECMO	Use of ECMO
Length of stay in NICU	Number of days from birth until discharge from NICU
Days of ventilatory support	Number of days of ventilatory support: mechanical ventilation, CPAP, optiflow. Low flow oxygen was not considered ventilatory support
Periventricular leukomalacia	As diagnosed by postnatal center using local criteria
Neonatal sepsis	As diagnosed by postnatal center using local criteria
Intraventricular hemorrhage ($> grade III$)	As diagnosed by postnatal center using local criteria
Retinopathy of prematurity	As diagnosed by postnatal center using local criteria
Days until full enteral feeding	Number of days from birth until full enteral feeding was established
Gastro-esophageal reflux	Above 1/3 of the esophagus on clinically indicated radiologic study
Day of postnatal surgery	Number of days from birth until the day of postnatal surgery
Use of patch	Use of patch at postnatal surgery
Defect size according to CDH study group ²	A: small defect, with muscular edges all around B: $< 50\%$ chest wall involvement C: $> 50\%$ chest wall involvement D: total agenesis of diaphragm
Date of postnatal death	Date
Survival to 6 months of age	Survival at 6 months of age
Exploratory outcomes	
Gestational age at FETO and balloon removal	Gestational age in weeks and days
Successful placement of balloon	Balloon positioned between carina and vocal cords
Anesthesia during FETO and balloon removal	Local / neuraxial / general

Chorioamniotic membrane separation	Echolucent space between membranes and uterine wall evidenced on ultrasound examination
Spontaneous deflation of balloon	No balloon visible inside the fetal trachea at follow up ultrasound or at the time of fetoscopic removal
Polyhydramnios after FETO	Presence of a deepest vertical pocket of ≥ 8 cm on ultrasound, diagnosed at any time point after FETO procedure
Gestational age at balloon removal	Gestational age in weeks and days
Emergency balloon removal	Balloon removal prior to scheduled date because of threatened preterm birth
Method of balloon removal	Fetoscopy / ultrasound guided puncture / postnatal
Interval balloon removal and delivery <24hrs	Duration between balloon removal and birth is less than 24 hours
Preterm prelabor rupture of membranes (PPROM) < 37 wks	Presence of ruptured membranes prior to 37 weeks gestational age
PPROM < 34 wks	Presence of ruptured membranes prior to 34 weeks gestational age
Gestational age at PPRM	Gestational age at membrane rupture, in weeks and days
Placental abruption	Occurrence of placental abruption
Gestational age at birth	Gestational age at birth, in weeks and days
Gestational age at birth < 32+0 wks	Birth < 32+0 wks
Gestational age at birth < 34+0 wks	Birth <34+0 wks
Gestational age at birth $\geq 37+0$ wks	Birth $\geq 37+0$ wks
Live born	Alive at birth
Birthweight	Birthweight in grams
Bronchopulmonary dysplasia according to Jobe and Bancalari ¹	Need for supplemental oxygen FiO ₂ >0.21 for at least 28 days. This is assessed at: <ul style="list-style-type: none"> - >28 days but <56 days postnatal age or discharge, whichever comes first; for infants born ≥ 32 weeks - 36 weeks postmenstrual age or discharge, whichever comes first, for infants born < 32 weeks
Necrotizing enterocolitis	Diagnosed by postnatal center using local criteria
Tracheomalacia	Diagnosed by postnatal center using local criteria
Survival to 28 days	Alive at day 28 after birth
Survival to 56 days	Alive at day 56 after birth
Exploratory safety endpoints	
IUFD < 24hrs after FETO	Occurrence of intrauterine fetal death within 24hrs after FETO procedure
IUFD at any point in pregnancy	Occurrence of intrauterine fetal death at any time point during pregnancy
Placental abruption < 24hrs after FETO	Occurrence of placental abruption within 24hrs after FETO procedure
Placental abruption at any point in pregnancy	Occurrence of placental abruption at any time point during pregnancy
Balloon removal issues	Any deviation from the normal course, or problem with balloon removal
Neonatal death due to failure of balloon removal	Neonatal death due to failure of balloon removal
Tracheomalacia	Diagnosed by postnatal center using local criteria
PPROM <37 wks	Presence of ruptured membranes prior to 37 weeks gestational age
Delivery <37 wks	Birth < 37+0 wks
Neonatal death <28 days	Neonatal death in the first 27 days
Death between 28 days and 6 months	Death between 28 days and 6 months after birth

Perinatal asphyxia (umbilical pH <7.00)	Umbilical artery pH <7.00
ECMO	Use of ECMO
Bronchopulmonary dysplasia according to Jobe and Bancalari ¹ in survivors to discharge	Need for supplemental oxygen FiO ₂ >0.21 for at least 28 days. This is assessed at: <ul style="list-style-type: none"> - >28 days but <56 days postnatal age or discharge, whichever comes first; for infants born ≥ 32 weeks - 36 weeks postmenstrual age or discharge, whichever comes first, for infants born < 32 weeks
Pulmonary hypertension in survivors to discharge	Based on evidence on cardiac ultrasound of predominant unidirectional right to left shunt.
Periventricular leukomalacia in survivors to discharge	As diagnosed by postnatal center using local criteria
Neonatal sepsis in survivors to discharge	As diagnosed by postnatal center using local criteria
Intraventricular hemorrhage > grade III in survivors to discharge	As diagnosed by postnatal center using local criteria
Retinopathy of prematurity in survivors to discharge	As diagnosed by postnatal center using local criteria
Polyhydramnios after FETO	Presence of a deepest vertical pocket of ≥ 8cm on ultrasound, diagnosed at any time point after FETO procedure
Chorioamniotic membrane separation	Echolucent space between membranes and uterine wall evidenced on ultrasound examination
Any additional adverse event (free text field)	

¹Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med.* 2001 Jun;163(7):1723-9.

²Tsao K, Lally KP. The congenital diaphragmatic hernia study group: a voluntary international registry. *Semin Pediatr Surg* 2008;17:90-7.

[Click to go to top of document: table of contents](#)

Supplementary Table S3: Associated anomalies diagnosed after randomization

Diagnosis	Time of diagnosis	Group	Included in per-protocol analysis (Yes/No)
Mutation filamin A gene	Postnatal	FETO	No
Mosaic trisomy 2	Postnatal	FETO	Yes
Duplication chromosome 8	Postnatal	FETO	Yes
Goldenhar	Postnatal	FETO	Yes
Simpson Golabi Behmel	Postnatal	FETO	No
Hypoplastic left heart syndrome	Postnatal	FETO	Yes
Tetrasomy 12p	Prenatal	Expectant	No
Tetrasomy 12p	Postnatal*	Expectant	Yes*
Fryns syndrome	Postnatal	Expectant	No

Summary of severe structural, genetic or syndromic diagnoses that were made **after** randomization. Inclusion into the per-protocol analysis was decided by the DMSC in consultation with two geneticists. 'Postnatal' (column 2) indicates the diagnosis was made during the postnatal period, though prior to discharge from the NICU. * In this infant, the diagnosis of tetrasomy 12p was made at one year of age, because of developmental delay. Because of the late diagnosis, the case was included by the DSMC in the per protocol analysis.

[Click to go to top of document: table of contents](#)

Supplementary Table S4: Operative outcomes in patients in the FETO arm.

Characteristic	
FETO procedure (n=98)	
FETO not performed – no. (%)	7/98 (7)
Failed placement of balloon – no. (%)	1/98 (1)
Successful placement of balloon – no. (%)	90/98 (92)
FETO attempted (n=91)	
Gestational age at FETO – wk	30.4 (30.1 – 30.8)
Anesthesia: local – no. (%)	35/91 (38)
Anesthesia: neuraxial block – no. (%)	56/91 (62)
Balloon removal procedure (n=90)	
Gestational age at balloon removal - wk	34.0 (33.2 – 34.3)
Spontaneous deflation no removal – no. (%)	1 (1)
Emergency balloon removal – no. (%)*	35 (39)
Gestational age - wk	33.0 (32.4 – 33.6)
Method: fetoscopic– no. (%)	24/35 (69)
Method: ultrasound guided puncture – no. (%)	4/35 (11)
Postnatal – no. (%)	7/35 (20)
Elective balloon removal – no. (%)	54 (60) ^a
Gestational age - wk	34.3 (34.1 – 34.6) ^a
Method: fetoscopic – no. (%)	53/54 (98) ^a
Method: ultrasound guided puncture – no. (%)	1/54 (2)
Interval between balloon insertion and removal	
Duration of tracheal occlusion – days [#]	24 (19 – 28)
Change in O/E LHR from baseline – %	32 (1 – 66) ^b
Interval between balloon removal and delivery	
< 24 hours – no. (%)	17/90 (19)

Continuous variables are reported as medians and interquartile ranges and categorical variables as absolute numbers and percentages. Abbreviations: FETO: fetoscopic endoluminal tracheal occlusion; O/E LHR: observed/expected lung-to-head ratio. ^aincluding two fetuses where the balloon was deflated; ^b six missing values. All exploratory outcomes except for change in O/E LHR from baseline.

* Reasons given were one or more of the following: prelabor membrane rupture (n=19), preterm labor (n=18), polyhydramnios (n=3), vaginal bleeding (n=2), large chorioamniotic membrane separation (n=1), delivery because of fetal growth restriction (n=1) or severe preeclampsia (n=1).

[#]excluding three cases with spontaneous deflations

[Click to go to top of document: table of contents](#)

Supplementary Table S5: Secondary neonatal outcomes in survivors at discharge

Outcome	FETO (n=62)	Expectant (n=49)
Days to neonatal repair of defect	3 (2-6)	2 (2-4)
ECMO days in survivors receiving ECMO (n=16)	6 (5-8)	7 (6-8)
Days of ventilatory support	25 (13-43)	28 (14-41)
Days to full enteral feeding	28 (17-40)	27 (18-40)
Bronchopulmonary dysplasia – no. (%) [°]	41/62 (66)	32/49 (65)
Mild	19/41 (46)	18/32 (56)
Moderate	11/41 (27)	7/32 (22)
Severe	11/41 (27)	7/32 (22)
Pulmonary hypertension – no. (%)	46/62 (74)	33/49 (67)
Periventricular leukomalacia – no. (%)	3/62 (5) ^a	1/49 (2) ^b
Sepsis – no. (%)	21/62 (34)	17/49 (35)
Intraventricular hemorrhage > grade III – no. (%)	0/62 (0)	0/49 (0)
Retinopathy of prematurity > grade 3 – no. (%)	0/62 (0)	0/49 (0)
Necrotizing enterocolitis – no. (%) [°]	2/62 (3)	0/49 (0)
Gastroesophageal reflux – no. (%) ^c	32/60 (53)	19/39 (49)
NICU days	49 (29-80)	46 (29-72)

Results are reported as absolute numbers and percentages (categorical variables) and or as medians and interquartile ranges (continuous variables) ^a all grade 1; ^b grade 3; ^c 12 missing values. [°]exploratory outcomes

[Click to go to top of document: table of contents](#)

Supplementary Table S6: Results of all interim analyses

Analysis stage	Date	Target N/arm	FETO, n (%)	Expectant management, n (%)	Difference between percentages	One-sided analysis ^c		Two-sided analysis ^c	
						p-value	Alpha ^d	p-value	Alpha ^d
Interim 1	Oct 15	40	24/40 (60.0)	18/40 (45.0)	15.0	0.0871	0.0005	0.1742	0.0010
Interim 2	Feb 17	59	37/59 (62.7)	28/59 (47.5)	15.3	0.0460	0.0036	0.0919	0.0072
Interim 3 ^a	Oct 17	69	45/70 (64.3)	33/68 (48.5)	15.8	0.0294	0.0064	0.0587	0.0128
Interim 4	Sep 18	79	51/79 (64.6)	38/79 (48.1)	16.5	0.0173	0.0099	0.0345	0.0198
Interim 5 ^b	Feb 19	89	57/89 (64.0)	43/88 (48.9)	15.2	0.0197	0.0140	0.0393	0.0280
Final	Mar 20	98	62/98 (63.3)	49/98 (50.0)	13.3	0.0293	0.0186	0.0587	0.0372


^a Due to a randomization error, there were 70 patients in FETO arm and 68 in the expectant management arm

^b One outcome in expectant management arm not available at time of analysis

^c The statistical design and analysis was done using a one-sided test (while controlling the overall alpha at 2.5%) focusing on superiority of FETO. We have post hoc added the two-sided results (overall alpha 5%), which equals twice the one-sided results if the observed effect favored FETO. With a two-sided approach, the direction of the observed effect must be checked.

^d The alpha level at each analysis stage is defined using the O'Brien-Fleming method in order to control the overall alpha at 2.5% (one-sided) or 5% (two-sided).

Observed survival rates for both study arms



[Click to go to top of document: table of contents](#)

Supplementary Table S7: Case load for postnatal management centers two years prior to their first trial patient.

Center	Y1	Y2
Hospital San Joan de Deu, Barcelona	14	14
Gregorio Maranon Hospital, Madrid	7	8
CHRU Montpellier, France	4	3
Universitätsklinikum Bonn	14	11
University Hospital Mannheim	46	59
Mater Mothers' Hospital, Brisbane	3	2
Women's and Children's Hospital, Adelaide	2	8
The Royal Women's Hospital and The Royal Children's Hospital, Melbourne	4	13
Hôpital Bicêtre, Le Kremlin-Bicêtre	17	13
CHU Amiens	6	3
CHU Caen	2	2
CHU de Bordeaux	6	6
CHU Clermont-Ferrand	7	4
CHU Rennes	2	3
CHU de Dijon	5	4
CHRU Lille	13	16
CHU Nancy	3	1
Hôpital Trousseau, Paris	7	6
Hôpital Robert Debré, Paris	8	8
CHU Saint Etienne	1	2
Hôpital Bretonneau, CHU Tours	7	13
Texas Children's Hospital, Houston	14	24
University of Michigan Hospital, Ann Arbor	12	22
University of Texas Health Science Center/ Children's Memorial Hermann, Houston	11	3
University Hospitals Leuven	15	11
Saint Luc UCL, Brussels	4	2
Medical University Hospital, Gdansk	3	0
LKH-Universitäts Klinikum Graz	4	4
Universitätsklinik Hamburg-Eppendorf	1	1
Radboudumc/Amalia Children's Hospital Nijmegen	6	22
The Institute for the Care of Mother and Child, Prague	8	18
Erasmus MC, Rotterdam	11	14
National Center for Fetal Medicine, Trondheim	6	2
University Hospital Zurich	8	7
King's College Hospital, London	23	20
St.George's Hospital, London	10	7
Chelsea and Westminster, London	12	12
Ospedale Maggiore Policlinico, Milano	15	18

Hôpital Necker – Enfants Malades, Paris	9	11
Ospedale Pediatrico Bambino Gesù, Rome	16	17
1 st Department of Obstetrics and Gynecology, Medical University of Warsaw	22	28

Seventeen neonatal management centers did not provide historical data.

[Click to go to top of document: table of contents](#)